Mark Schoenberg - 07 Sep 2023 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
07 Sep 2023
Net transactions value
$0
Form type
4
Filing time
08 Sep 2023, 15:40:34 UTC
Previous filing
09 Jun 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Award $0 +5,000 $0.000000 5,000 07 Sep 2023 Ordinary Shares 5,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 1/3 of the shares underlying the restricted stock units will vest on each of September 7, 2024, September 7, 2025 and September 7, 2026